Qure.ai provides an artificial intelligence for radiology

Nova Satra Dx provides highly accurate and innovative diagnostics

New drugs to treat brain diseases

New gene-editing technique could drive out mosquito-borne disease

A novel way to edit the genome of disease-carrying mosquitoes that brings us closer to suppressing them on a continental scale has been developed by the researchers at the University of California, Berkeley (UC Berkeley). The study used CRISPR/Cas9 gene-editing technology to insert and spread genes designed to suppress wild insects, while at the same time avoiding the resistance to these efforts that evolution would typically favor. The proof-of-concept study was demonstrated in fruit flies; but the researchers believe this technology could be used in mosquitoes to help fight malaria and other mosquito-borne diseases in the next decade, pending public and regulatory approval.

1 day ago

X-ZELL: fighting cancer, one cell at a time

X-ZELL is a global biotechnology company aiming to fundamentally reshuffle the way of diagnosing and managing one of the most pressing health issues of the time – cancer (lat. Carcinoma). The company was founded in 2014 in Singapore. Ranked among Asia’s 20 most innovative health technology start-ups, X-ZELL has developed a new platform technology capable of detecting tumour-derived Circulating Endothelial Cells (tCEC) in a small, 10mL blood sample. Long considered ‘undetectable’ in clinical routine, these ultra-rare cells help physicians diagnose clinically significant cancer early when it can be cured – in turn avoiding more than 70% of unnecessary interventions and saving billions to health systems worldwide.

1 day ago

The new gene therapy to develop treatments for central nervous system

The new treatment for the central nervous system (lat. Systematis nervosi centralis) was developed by Lacerta Therapeutics. The company is a clinical-stage gene therapy company using a constellation of proprietary adeno-associated virus (AAV) vector technologies to develop treatments for the central nervous system and lysosomal storage diseases. With unmatched scientific expertise and depth in the development, production, and application of AAV vectors, Lacerta Therapeutics is advancing its clinical programs using its proprietary capsid variants and scalable vector manufacturing platform. The experience and accomplishments of the Lacerta Therapeutics founders are unsurpassed in AAV gene therapy. They are actively seeking collaborative partnership and out-licensing opportunities providing potential partners with numerous advantages over current AAV vector platforms. Their AAV expertise and platforms allow offering early access to novel capsid variant identification and robust, scalable vector manufacturing.

4 days ago

Innovative therapies for patients suffering from Central Nervous System diseases

ViTi: diagnosing infectious diseases

Neuway Pharma: qualified for cns drug delivery

CNS Therapy: the defibrillator for chronic pain

CNS Therapy, a spinoff from the University of North Carolina (UNC), contributes to human well-being through mind-body therapy and the research, design, education, and sale of devices that alleviate chronic disease, restore health, and extend useful life. The company's base technology is a patent-pending approach to chronic pain which combines operant behavioural therapy with a proprietary device which enhances learning and resets the autonomic nervous system – called SET – Systolic Extinction Training.  CNS Therapy is dedicated to providing long-lasting pain relief to patients. Its unique combination of psychological training and electrostimulation helps chronic pain patients to starkly reduce or even eliminate their pain and allow them to return to their daily lives.

4 days ago

Researchers could dramatically fast-track the detection of mental and neurological illnesses

Central Nervous System (lat. Systematis nervosi centralis, CNS) disorders place huge social and financial pressure on communities around the world. One in four people will have one sometime in their life, they cost upwards of US$2 trillion globally, and they can take more than a decade to correctly diagnose. The suffering of patients and carers is often compounded because appropriate treatment is delayed and sometimes comes too late. Biomedical engineer Brian Lithgow at Monash University has developed what he hopes could be a solution. His invention, something akin to an 'ECG for the mind', measures the shifting electrical activity of the brain and, more specifically, the vestibular or balance system.

4 days ago

Understanding brain functions using upconversion nanoparticles

Scientists from the National University of Singapore (NUS) have worked with an international research team to jointly develop a novel approach for deep brain stimulation. The new method utilises upconversion nanoparticles developed by Professor Liu Xiaogang from the Department of Chemistry at NUS Faculty of Science to allow delivery of visible light deep into the brain to stimulate neural activities in a less-invasive manner. This innovation marks a significant breakthrough in optogenetics, empowering researchers to uncover valuable insights about the brain. Furthermore, the technology will pay the way to new therapies for neurological disorders (lat. Neurological morbis) such as Parkinson’s disease.

4 days ago

Cookies help us deliver our Services. By using our website or clicking I agree, you agree to our use of cookies. Learn more about our cookie and privacy policy.



100% Free of Cost For Scientists:

  • One hour of USA/EU attorney consulting
  • 24/7 support of 24 in-house professionals
  • 10 GB space for every scientist (own German Servers)
  • Syndicates with the leading professionals
  • 2,000 000 views of top spinoff are guaranteed
  • The largest DB of professional Investors - over 30.000

100% Free of Cost For Investors:

  • Investment information on 8,000+ spinoffs per year
  • All documents in one place (after NDA)
  • Testimonials from Key Opinion Leaders
  • AI-SDB hides irrelevant spinoffs - saved time up to 90% 
  • One-Click-Reports (OCRs) in own tailored design (PDF)

100% Free of Cost For Universities:

  • Professional Science Spinoff University Report (PDF)
  • No Links to Spinoff.com - Ready to Print and Share
  • Professional dossiers on over 27Tsd VC/PE/FO/ML
  • Professional dossiers on over 3Tsd MNC